{"id":659175,"date":"2023-07-12T07:42:01","date_gmt":"2023-07-12T07:42:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=659175"},"modified":"2023-07-12T07:42:01","modified_gmt":"2023-07-12T07:42:01","slug":"sly-syndrome-market-to-witness-growth-during-the-forecast-period-202332-estimates-delveinsight-key-companiesultragenx-pharma-centogene-gmbh","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/sly-syndrome-market-to-witness-growth-during-the-forecast-period-202332-estimates-delveinsight-key-companiesultragenx-pharma-centogene-gmbh_659175.html","title":{"rendered":"Sly Syndrome Market to Witness Growth During the Forecast Period (2023-32), Estimates DelveInsight | Key Companies-UltraGenx Pharma, CentoGene GmBh"},"content":{"rendered":"
\n
\"Sly<\/a><\/div>\n
\n
DelveInsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n
(Las Vegas, Nevada, United States),”DelveInsight’s “Sly Syndrome Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Sly Syndrome, historical and forecasted epidemiology as well as the Sly Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.<\/div>\n

(Las Vegas, Nevada, United States),”DelveInsight’s “Sly Syndrome Market Insights, Epidemiology, and Market Forecast-2032<\/a><\/strong>” report delivers an in-depth understanding of the Sly Syndrome, historical and forecasted epidemiology as well as the Sly Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.<\/p>\n

Sly Syndrome Overview<\/strong><\/p>\n

The sly syndrome is caused by a deficiency of the enzyme beta-glucuronidase, and it was the first MPS for which the altered gene was localized to an autosome chromosome, the long arm of the chromosome. Sly syndrome, also called mucopolysaccharidosis type VII (MPS-VII), is an autosomal recessive lysosomal storage disease caused by a deficiency of the enzyme β-glucuronidase. This enzyme is responsible for breaking down large sugar molecules called glycosaminoglycans (AKA GAGs, or mucopolysaccharides). The inability to break down GAGs leads to a buildup in many tissues and organs of the body. The severity of the disease can vary widely.<\/p>\n

\"\"<\/p>\n

Sly Syndrome Epidemiological Insights<\/strong><\/p>\n

MPS-VII is one of the rarest forms of MPS. It occurs in less than 1 in 250,000 births. As a family, MPS diseases occur in 1 in 25,000 births, and the larger family of lysosomal storage diseases occur in 1 out of 7,000 to 8,000 births<\/p>\n

 <\/p>\n

 Leading Companies Working in the Sly Syndrome Market<\/strong><\/p>\n